stockrowTwist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) Revenue
Twist Bioscience Corporation's revenue for fiscal 2025 was $376.6M, up 20.3% from $313.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $431.8M. Over the past ten years it has ranged from $2.3M (fiscal 2016) to $376.6M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 9 consecutive fiscal years. Twist Bioscience Corporation ranks 44th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $376.6M | 20.32% |
| FY2024 | $313.0M | 27.69% |
| FY2023 | $245.1M | 20.41% |
| FY2022 | $203.6M | 53.83% |
| FY2021 | $132.3M | 46.87% |
| FY2020 | $90.1M | 65.67% |
| FY2019 | $54.4M | 113.89% |
| FY2018 | $25.4M | 136.16% |
| FY2017 | $10.8M | 374.53% |
| FY2016 | $2.3M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $118.4M | 6.92% |
| Mar 2026 | $110.7M | 6.77% |
| Dec 2025 | $103.7M | 4.74% |
| Sep 2025 | $99.0M | 3.07% |
| 31 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. compare | $1.4B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| TGTX TG Therapeutics, Inc. compare | $799.5M |
| KRYS Krystal Biotech, Inc. compare | $470.0M |
| TWST Twist Bioscience Corporation | $431.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $282.0M |
| IBRX ImmunityBio, Inc. compare | $165.8M |
| CYTK Cytokinetics, Incorporated compare | $113.3M |
| SYRE Spyre Therapeutics, Inc. compare | $1.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TWST
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement